Adjuvant Development Program

Added: Oct 02, 2008 10:40 am The purpose of this solicitation is to establish a new Adjuvant Development Program to advance a novel class of vaccine adjuvants towards licensure for human use. This novel class of adjuvants stimulates the innate immune response and demonstrates strong adjuvant properties in animal models. These candidate vaccine adjuvants will be developed for human use with currently licensed or new investigational vaccine immunogens, to protect against NIAID Category A, B, or C Priority Pathogens. This initiative supports the development of candidate vaccine adjuvants through immunological characterization studies, lead compound optimization, and/or Investigational New Drug (IND)-enabling studies, for a period not to exceed five (5) years. Work must include studies on at least one Category A, B, or C Priority Pathogen. Additional studies may be focused on other human infectious pathogens with sufficient justification of an ultimate application to Biodefense. Studies with HIV will not be supported.